Raccah D, Coste T, Cameron N E, Dufayet D, Vague P, Hohman T C
Laboratory of Diabetology, University Timone Hospital, Marseille, France.
J Diabetes Complications. 1998 May-Jun;12(3):154-62. doi: 10.1016/s1056-8727(97)00093-7.
Long-term prospective studies comparing the effects of conventional and intensive insulin therapy have linked diabetic hyperglycemia to the development of diabetic retinopathy, nephropathy, and neuropathy. The mechanisms through which glucose metabolism leads to the development of these secondary complications, however, are incompletely understood. In animal models of diabetic neuropathy, the loss of nerve function in myelinated nerve fibers has been related to a series of biochemical changes. Nerve glucose, which is in equilibrium with plasma glucose levels, rapidly increases during diabetic hyperglycemia because glucose entry is independent of insulin. This excess glucose is metabolized in large part by the polyol pathway. Increased flux through this pathway is accompanied by the depletion of myo-inositol, a loss of Na/K ATPase activity and the accumulation of sodium. Supportive evidence linking these biochemical changes to the loss of nerve function has come from studies in which aldose reductase inhibitors block polyol pathway activity, prevent the depletion of myo-inositol and the accumulation of sodium and preserve Na/K ATPase activity, as well as nerve function. The kidney and red blood cells (RBCs) are two additional sites of diabetic lesions that have been reported to develop biochemical changes similar to those in the nerve. We observed that polyol levels in the kidney cortex, medulla, and RBCs increased two- to ninefold in rats following 10 weeks of untreated diabetes. Polyol accumulation was accompanied by a 30% decrease in myo-inositol levels in the kidney cortex, but no change in RBCs or the kidney medulla. Na/K ATPase activity was decreased by 59% in RBCs but was unaffected in the kidney cortex or medulla. Aldose reductase inhibitor treatment that preserved myo-inositol levels, Na/K ATPase, and conduction velocity in the sciatic nerve also preserved Na/K ATPase activity in RBCs. Our results suggest that the pathophysiologic mechanisms underlying diabetic neuropathy are different from those of diabetic nephropathy. Our results also suggest that RBCs maybe a surrogate tissue for the assessment of diabetes-induced changes in nerve Na/K ATPase activity.
比较传统胰岛素治疗和强化胰岛素治疗效果的长期前瞻性研究已将糖尿病高血糖与糖尿病视网膜病变、肾病和神经病变的发生联系起来。然而,葡萄糖代谢导致这些继发性并发症发生的机制尚未完全明确。在糖尿病神经病变的动物模型中,有髓神经纤维神经功能的丧失与一系列生化变化有关。神经葡萄糖与血浆葡萄糖水平处于平衡状态,在糖尿病高血糖期间会迅速增加,因为葡萄糖进入神经细胞不依赖胰岛素。这些过量的葡萄糖大部分通过多元醇途径代谢。该途径通量增加的同时伴随着肌醇的消耗、钠钾ATP酶活性的丧失以及钠的蓄积。将这些生化变化与神经功能丧失联系起来的支持性证据来自于一些研究,在这些研究中,醛糖还原酶抑制剂可阻断多元醇途径活性,防止肌醇消耗和钠蓄积,并维持钠钾ATP酶活性以及神经功能。肾脏和红细胞是另外两个已报道发生类似神经病变生化变化的糖尿病病变部位。我们观察到,未经治疗的糖尿病大鼠持续10周后,肾皮质、髓质和红细胞中的多元醇水平增加了2至9倍。多元醇蓄积伴随着肾皮质中肌醇水平降低30%,但红细胞和肾髓质中未发生变化。红细胞中的钠钾ATP酶活性降低了59%,但肾皮质或髓质中未受影响。醛糖还原酶抑制剂治疗可维持坐骨神经中的肌醇水平、钠钾ATP酶和传导速度,同时也能维持红细胞中的钠钾ATP酶活性。我们的结果表明,糖尿病神经病变的病理生理机制与糖尿病肾病不同。我们的结果还表明,红细胞可能是评估糖尿病引起的神经钠钾ATP酶活性变化的替代组织。